Back
Full-text
Journal article

Rationally designed ruthenium complexes for 1- and 2-photon photodynamic therapy.

  • Karges J Chimie ParisTech, PSL University, CNRS, Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, 75005, Paris, France.
  • Kuang S MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Sun Yat-sen University, Guangzhou, 510275, P.R. China.
  • Maschietto F Chimie ParisTech, PSL University, CNRS, Institute of Chemistry for Life and Health Sciences, Theoretical Chemistry and Modelling, 75005, Paris, France.
  • Blacque O Department of Chemistry, University of Zurich, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland.
  • Ciofini I Chimie ParisTech, PSL University, CNRS, Institute of Chemistry for Life and Health Sciences, Theoretical Chemistry and Modelling, 75005, Paris, France.
  • Chao H MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Sun Yat-sen University, Guangzhou, 510275, P.R. China. ceschh@mail.sysu.edu.cn.
  • Gasser G Chimie ParisTech, PSL University, CNRS, Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, 75005, Paris, France. gilles.gasser@chimieparistech.psl.eu.
Show more…
  • 2020-06-28
Published in:
  • Nature communications. - 2020
Animals
Cell Proliferation
Cell Survival
Coordination Complexes
Drug Design
Female
HeLa Cells
Humans
Mice, Nude
Photochemotherapy
Photons
Ruthenium
Singlet Oxygen
Spectrum Analysis
Spheroids, Cellular
English The use of photodynamic therapy (PDT) against cancer has received increasing attention over recent years. However, the application of the currently approved photosensitizers (PSs) is limited by their poor aqueous solubility, aggregation, photobleaching and slow clearance from the body. To overcome these limitations, there is a need for the development of new classes of PSs with ruthenium(II) polypyridine complexes currently gaining momentum. However, these compounds generally lack significant absorption in the biological spectral window, limiting their application to treat deep-seated or large tumors. To overcome this drawback, ruthenium(II) polypyridine complexes designed in silico with (E,E')-4,4'-bisstyryl-2,2'-bipyridine ligands show impressive 1- and 2-Photon absorption up to a magnitude higher than the ones published so far. While nontoxic in the dark, these compounds are phototoxic in various 2D monolayer cells, 3D multicellular tumor spheroids and are able to eradicate a multiresistant tumor inside a mouse model upon clinically relevant 1-Photon and 2-Photon excitation.
Language
  • English
Open access status
gold
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/271335
Statistics
Document views: 11 File downloads:
  • fulltext.pdf: 0